TNFRSF17 and plasma cell myeloma: These molecules are engineered to simultaneously bind to a tumor-associated antigen [such as BCMA or G protein-coupled receptor, class C group 5 member D (GPRC5D)] on myeloma cells and CD3 on T cells, thereby redirecting T-cell cytotoxicity against malignant plasma cells [12,13].